BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200709T030000
DTEND;TZID=America/New_York:20200709T043000
DTSTAMP:20260503T052858
CREATED:20200330T142214Z
LAST-MODIFIED:20200422T140818Z
UID:3939-1594263600-1594269000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
DESCRIPTION:Speakers: \n\nAnand Anandkumar\, Co-founder and CEO Bugworks Research Inc (India)\nKamini Walia\, Program Officer\, ICMR-AMR Initiative (India) \n\nModerator: François Franceschi\, GARDP  \nIn this webinar\, Anand Anandkumar and Kamini Walia will discuss: \n\nWhy is India one of the hotbeds of the AMR problem? Latest statistics of growing drug resistance etc.\nInitiatives of the Indian Government to curb the AMR problem\nAntimicrobial R&D landscape in India – a vibrant ecosystem supporting innovation in AMR diagnosis\, prevention and therapeutics\nFledgling antimicrobial clinical trial networks – could trials out of India play a significant role in gaining global regulatory approvals?\nChanging regulatory environment to enable accelerated approvals for antimicrobial products\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 5 May 2020\, 9:00-10:30 am CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-the-challenges-and-opportunities-for-antimicrobial-rd-in-low-and-middle-income-countries-india-case-study/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200630T110000
DTEND;TZID=America/New_York:20200630T123000
DTSTAMP:20260503T052858
CREATED:20200406T155840Z
LAST-MODIFIED:20200422T140757Z
UID:3950-1593514800-1593520200@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Clinical development of antimicrobials – Phase 1 development challenges
DESCRIPTION:Speaker: Markus Zeitlinger\, Head of Department of Clinical Pharmacology\, Medical University of Vienna (Austria) \nModerator: Markus Heep \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 30 June\, 17:00-18:30 CEST. Find your time zone here.
URL:https://carb-x.org/event/live-webinar-gardp-revive-clinical-development-of-antimicrobials-phase-1-development-challenges/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200609T110000
DTEND;TZID=America/New_York:20200609T123000
DTSTAMP:20260503T052858
CREATED:20200330T142524Z
LAST-MODIFIED:20200422T140732Z
UID:3943-1591700400-1591705800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
DESCRIPTION:Speaker: Vincent H. Tam\, Professor\, University of Houston College of Pharmacy (USA) \nModerator: Shampa Das\, Senior Lecturer\, Centre of Excellence in Infectious Diseases Research\, University of Liverpool (UK)  \nIn this webinar\, Vincent H. Tam will present on his work looking at studying PK/PD in fixed dose beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations. \nTopics discussed will include: \n\nUnderstanding the inherent challenges associated with PK/PD of BL/BLI combinations\nDemonstrating new approaches to gain useful insights from preclinical PK/PD models\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 9 June 2020\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-test-tube-to-patient-pk-pd-of-fixed-dose-beta-lactam-beta-lactamase-inhibitor-combinations/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200528T120000
DTEND;TZID=America/New_York:20200528T130000
DTSTAMP:20260503T052858
CREATED:20200504T145415Z
LAST-MODIFIED:20200504T145415Z
UID:3997-1590667200-1590670800@carb-x.org
SUMMARY:Live Webinar – CARB-X - How to Prepare for an FDA Pre-IND Meeting: Planning for Success
DESCRIPTION:Speakers: \nCarmella Moody\, Regulatory Program Director\, RTI International \nMichael Bevilacqua\, M.D.\, Ph.D.\, Chief Executive Officer and Chief Science Officer\, Amicrobe Inc. \nIn this webinar\, Carmella Moody and Michael Bevilacqua will help product developers understand how best to prepare for pre-IND meetings to ensure maximum results. \nCarmella Moody has many years experience supporting and preparing companies for pre-IND meetings. Michael Bevilacqua\, who worked with CARB-X to prepare for his company’s recent pre-IND meeting\, will discuss his positive experience and lessons learned.  Everyone is welcome to join. A recording of the webinar will be available for those who cannot attend the live broadcast. \nPresentations will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on May 28\, 12:00 to 13:00 ET (find your time zone here).
URL:https://carb-x.org/event/live-webinar-carb-x-how-to-prepare-for-an-fda-pre-ind-meeting-planning-for-success/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200519T110000
DTEND;TZID=America/New_York:20200519T123000
DTSTAMP:20260503T052858
CREATED:20200422T141057Z
LAST-MODIFIED:20200422T141057Z
UID:3982-1589886000-1589891400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Assay development for measuring antibiotic accumulation in Gram-negative bacteria
DESCRIPTION:Speakers: \n\nJessica Blair\, Institute of Microbiology and Infection\, University of Birmingham (UK)\nMark Brönstrup\, Department of Chemical Biology\, Helmholtz Centre for Infection Research (Germany)\nDavid A. Six\, Venatorx Pharmaceuticals\, Inc. (US)\n\nModerator: Alice Erwin\, Erwin Consulting LLC (US) \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-assay-development-for-measuring-antibiotic-accumulation-in-gram-negative-bacteria/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200512T110000
DTEND;TZID=America/New_York:20200512T123000
DTSTAMP:20260503T052858
CREATED:20200330T142407Z
LAST-MODIFIED:20200422T140709Z
UID:3941-1589281200-1589286600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Probability of target attainment analyses for dose selection in antimicrobial drug development
DESCRIPTION:Speaker: Shampa Das\, Senior Lecturer\, Centre of Excellence in Infectious Diseases Research\, University of Liverpool (UK)  \nModerator: Vincent H. Tam\, Professor\, University of Houston (US)  \nIn this webinar\, Shampa Das will give an overview of her work in studying the PK/PD and probability of target attainment for dose selection. \nTopics discussed will include: \n\nAn overview of what is meant by the probability of target attainment (PTA)\nHow it is calculated and what data is used for this\nHow PTA is used for decision making during drug development\n\nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 12 May 2020\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-probability-of-target-attainment-analyses-for-dose-selection-in-antimicrobial-drug-development/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200428T110000
DTEND;TZID=America/New_York:20200428T123000
DTSTAMP:20260503T052858
CREATED:20200330T142019Z
LAST-MODIFIED:20200422T140647Z
UID:3937-1588071600-1588077000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Inhaled antimicrobials: Do we get the drug to the bug?
DESCRIPTION:Speaker: Harm A. W. M. Tiddens\, Professor of Pediatric Pulmonology and Allergology\, Erasmus Medical Center Sophia Children’s Hospital (Netherlands) \nModerator: Harpal Singh Dhillon\, Global Medical Value Director & Founder\, AntiBx (UK)\n \nIn this webinar\, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this can impact upon the deposition pattern and efficacy of inhaled antibiotics. He will further present the learnings of his research group’s computational fluid dynamic modelling studies and explain why the expectation that inhaled antibiotics result in high concentrations in the lung is unfortunately a misconception. \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar including interactive Q&A session on 28 April\, 17:00-18:30 CEST (find your time zone here).
URL:https://carb-x.org/event/live-webinar-gardp-revive-inhaled-antimicrobials-do-we-get-the-drug-to-the-bug/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200227T110000
DTEND;TZID=America/New_York:20200227T123000
DTSTAMP:20260503T052858
CREATED:20200127T163753Z
LAST-MODIFIED:20200127T163906Z
UID:3761-1582801200-1582806600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - PK/PD murine infection models: Focus on study elements\, variability\, and interpretation of results
DESCRIPTION:In this webinar\, Alexander J. Lepak will review critical study elements that lead to robust preclinical PK/PD results in the murine model. \nTopics discussed will include: \n\nUnderstanding and embracing the inherent variability in many components of the murine model\nDemonstrating how to generate and interpret preclinical murine model PK/PD results\n\nThe presentation will be followed by a Q&A session. \nThe material presented in this webinar was shown but not recorded at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019. \nSpeaker: Alexander J. Lepak\, Assistant Professor\, Department of Medicine\, University of Wisconsin School of Medicine and Public Health (USA) \nModerator: Peter Warn\, Evotec (UK) \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-pk-pd-murine-infection-models-focus-on-study-elements-variability-and-interpretation-of-results/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200204T110000
DTEND;TZID=America/New_York:20200204T123000
DTSTAMP:20260503T052858
CREATED:20200127T162038Z
LAST-MODIFIED:20200127T162038Z
UID:3752-1580814000-1580819400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Non-traditional antibacterial therapeutic options and challenges
DESCRIPTION:In this webinar\, the following aspects will be presented: \n\nDiscovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline\nThese approaches include anti-virulence strategies\, microbiome-modifying therapies\, phages and others such as nanoparticles\, immunotherapy and drug-resistance modulation\nSome of these approaches require novel preclinical efficacy models to predict clinical outcome\nPathogen-specific or even patient-specific strategies dominate this field\nA major challenge will be to show efficacy in clinical trials\n\nThe presentation will be followed by a Q&A session with Ursula Theuretzbacher and Laura Piddock (GARDP). \nSpeaker: Ursula Theuretzbacher\, CEFAIA\, Austria \nModerator: Prabhavathi Fernandes\, Chair of GARDP’s Scientific Advisory Committee \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-non-traditional-antibacterial-therapeutic-options-and-challenges/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191126T033000
DTEND;TZID=America/New_York:20191126T050000
DTSTAMP:20260503T052858
CREATED:20191031T131530Z
LAST-MODIFIED:20191113T153543Z
UID:3583-1574739000-1574744400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Innovation in point-of-care diagnostics for sepsis and bloodstream infections
DESCRIPTION:In this webinar our moderator Caroline Purslow (Nesta Challenges) will welcome three speakers. \nTill Bachmann (University of Edinburgh) will give an overview of recent advances in AMR diagnostics development. He will discuss: \n\nState of the art approaches for diagnosing infections and AMR\nPipeline of promising tests\nChallenges of adoption\n\nAmrita Sukrity (SpotSense) will draw from her experience as a founder of SpotSense and talk about diagnosis of neonatal sepsis at the community level. Topics discussed will include: \n\nChallenges across diagnosing newborn sepsis in NICU vs. in the community\nIdentifying different phases of sepsis by combining risk parameters and biomarker data\nCreating outlines for biomarker-based differential diagnosis: work ahead\n\nAnd finally\, David Anderson’s (Burnet Institute) presentation ‘CD64 as a host-response biomarker in sepsis and severe infections’ will cover: \n\nLimitations of flow cytometry for CD64 as a diagnostic tool of sepsis and severe infections in emergency situations\nNovel observations on CD64 biology that should facilitate more sensitive a point-of-care (POC) diagnostic tests for sepsis and severe infections\nThe ongoing development of a POC diagnostic test for neutrophil CD64\n\nThe presentations will be followed by a Q&A session. \nRegister here for this live webinar. \nA recording of this webinar will be available on revive.gardp.org/webinars.
URL:https://carb-x.org/event/live-webinar-gardp-revive-innovation-in-point-of-care-diagnostics-for-sepsis-and-bloodstream-infections/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191107T110000
DTEND;TZID=America/New_York:20191107T123000
DTSTAMP:20260503T052858
CREATED:20190913T040059Z
LAST-MODIFIED:20190913T154657Z
UID:3423-1573124400-1573129800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Converting Gram-positive-only compounds into broad-spectrum antibiotics
DESCRIPTION:This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois\, US) will detail his research group’s efforts to understand compound accumulation in the Gram-negative ESKAPE pathogens. Emphasis will be placed on the practicality\, actionability\, and translatability of this information\, specifically\, the use of accumulation rules to convert high-value Gram-positive-only compounds into antibiotics with activity against key Gram-negative pathogens. \nThe presentation will be followed by a Q&A session. \nSpeaker:\nPaul Hergenrother\, Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry\, University of Illinois \nModerator:\nLaura Piddock\, Director of Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-converting-gram-positive-only-compounds-into-broad-spectrum-antibiotics/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191011T120000
DTEND;TZID=America/New_York:20191011T130000
DTSTAMP:20260503T052858
CREATED:20190923T195010Z
LAST-MODIFIED:20190926T124915Z
UID:3463-1570795200-1570798800@carb-x.org
SUMMARY:Live Webcast: Drug-Resistant Infections: Confronting an Escalating Crisis
DESCRIPTION:Antibiotics are a pillar of modern medicine. They have saved millions of lives and added some 20 years to human life expectancy. But as the use of antibiotics has increased\, so has the proliferation of antibiotic-resistant microbes that have adapted to survive most\, or all\, of today’s antibiotics. The CDC reports that two million people are infected with drug-resistant bacteria every year in the United States\, and the Review on Antimicrobial Resistance estimated that\, around the world\, 700\,000 people die of such infections annually. That number stands to increase: the Review predicts that\, by 2050\, drug resistance could be responsible for 10 million deaths a year. And while these numbers are dominated by bacterial infections\, fungal infections like Candida auris are also a threat\, especially to vulnerable patients in hospitals and nursing homes. \nDespite drug resistance growing\, the development of new antibiotics has slowed. How can policymakers help accelerate the pace of new drug development. How can all of us—doctors\, hospitals\, and patients\, as well as the agricultural sector—be better stewards of existing drugs? Forum panelists will examine the scope of this looming crisis and look at how changes in policy and practice can help us stay one step ahead of these superbugs. \nModerator\nDavid Freeman\, Editorial Director of NBC News MACH \nPanelists\nHelen Boucher\, Director\, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR) and Professor of Medicine at Tufts University School of Medicine \nLauri Hicks\, Director\, Office of Antibiotic Stewardship\, Centers for Disease Control and Prevention \nMarc Lipsitch\, Professor of Epidemiology and Director of the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health \nKevin Outterson\, Executive Director of CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)\, and Professor of Law\, Boston University \nPart of: The Dr. Lawrence H. and Roberta Cohn Forums.\nPresented jointly with NBC News Digital \nLive webcast will be on Friday\, October 11\, 2019\, 12:00pm – 1:00pm ET.\nAn on-demand video will be posted after the event. \nTo learn more\, click here.
URL:https://carb-x.org/event/live-webcast-drug-resistant-infections-confronting-an-escalating-crisis/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191003T110000
DTEND;TZID=America/New_York:20191003T123000
DTSTAMP:20260503T052858
CREATED:20190729T133232Z
LAST-MODIFIED:20190729T133501Z
UID:3229-1570100400-1570105800@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Natural products antibiotics: from traditional screening to novel discovery approaches
DESCRIPTION:In this webinar\, Olga Genilloud will discuss the role of natural products in current antibiotic discovery. Topics discussed will include: \n\nScreening strategies to identify novel antibiotics\nCurrent challenges and novel analytical tools\nNew omic approaches supporting antibiotic discovery\n\nThe presentation will be followed by a Q&A session. \n  \nSpeaker: \nOlga Genilloud\, Scientific Director\, Fundación MEDINA\, Granada\, Spain \nModerator: \nLaura Piddock\, Director of Scientific Affairs\, GARDP \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-natural-products-antibiotics-from-traditional-screening-to-novel-discovery-approaches/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190910T110000
DTEND;TZID=America/New_York:20190910T123000
DTSTAMP:20260503T052858
CREATED:20190729T132915Z
LAST-MODIFIED:20190729T133433Z
UID:3226-1568113200-1568118600@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research
DESCRIPTION:In this webinar\, Peter Warn will review the experimental design and conduct of advanced or complex animal models for antimicrobial research. \nThis webinar is designed as a follow on from the webinar of William J. Weiss: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research (see here: http://bit.ly/2ZiPt6y). \nTopics covered in this webinar will include: \n\nIn depth review of animal models of pneumonia\, UTI and tissue infections including biofilm models.\nAnimal models of non-traditional drugs where CFU might not be a suitable biomarker.\nTips\, hints and pitfalls when trying to generate informative data in PKPD studies.\n\nThe presentation will be followed by a Q&A session. \n  \nSpeaker: \nPeter Warn\, Senior Vice President\, Anti-infective Discovery\, Evotec \nModerator: \nWilliam J. Weiss\, Director\, PreClinical Services\, University of North Texas System College of Pharmacy \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-models-for-antimicrobial-rd-advanced-and-complex-in-vivo-models-for-infectious-disease-research/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190820T110000
DTEND;TZID=America/New_York:20190820T123000
DTSTAMP:20260503T052858
CREATED:20190723T181013Z
LAST-MODIFIED:20190723T181112Z
UID:3210-1566298800-1566304200@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE - Models for antimicrobial R&D: Computational modelling for population PK and PKPD
DESCRIPTION:The overall goal of this series of webinars is to provide\, for the non-clinical developer\, an understanding of the risks of development for various kinds of antibacterial products. \nIn this webinar\, Lena Friberg and Elisabet Nielsen (Department of Pharmaceutical Biosciences\, Uppsala University\, Sweden)\, will discuss: \n\nPopulation PK modelling to characterize drug exposure and variability\nPKPD-modelling to characterize preclinical time-kill data\nPKPD-modelling for translation to patients\nModel-based dose-individualization\n\nThe presentation will be followed by a Q&A session. \n  \nSpeakers: \nLena Friberg and Elisabet Nielsen\, Department of Pharmaceutical Biosciences\, Uppsala University\, Sweden \nModerator: \nUrsula Theuretzbacher\, Center for Anti-Infective Agents\, Vienna\, Austria \nRegister here for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-models-for-antimicrobial-rd-computational-modelling-for-population-pk-and-pkpd/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Helsinki:20190521T170000
DTEND;TZID=Europe/Helsinki:20190521T183000
DTSTAMP:20260503T052858
CREATED:20190314T170711Z
LAST-MODIFIED:20190404T155846Z
UID:2558-1558458000-1558463400@carb-x.org
SUMMARY:GARDP Mining Chemical Libraries for New Antibacterials
DESCRIPTION:Despite the promise of target-based drug discovery ushered in by the genomics era\, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds\, which mainly come from mining various chemical libraries. In this webinar\, Carl Balibar (Merck Research Laboratories) will discuss screen design\, target bias\, and hit-prioritization strategies to identify those entities with the greatest opportunity to be developed into the next new antibiotic. \nThe overall goal of this series of webinars is to provide\, for the non-clinical developer\, an understanding of the risks of development for various kinds of antibacterial products. In this third webinar\, we will discuss the development of antibacterial drug enhancer combinations and non-traditional products. \nPlease note\, this webinar has been rescheduled from April 4th to May 21st\, 2019. \nThe webinar will be held from 5:00 pm – 6:30 pm CEST / 11:00 pm – 12:30 pm EDT. \nThe presentation will be followed by a Q&A session. \nRegister here for this live webinar.
URL:https://carb-x.org/event/mining-chemical-libraries-for-new-antibacterials/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190516T090000
DTEND;TZID=America/New_York:20190516T100000
DTSTAMP:20260503T052858
CREATED:20190509T203055Z
LAST-MODIFIED:20190528T161825Z
UID:2992-1557997200-1558000800@carb-x.org
SUMMARY:Live Webinar: CARB-X 2019 Funding Rounds
DESCRIPTION:Kevin Outterson\, CARB-X Executive Director\, and Karen Gallant\, CARB-X Global R&D Project Director\, present details of CARB-X’s four new funding rounds announced April 30\, 2019\, and answer questions during this webinar. To attend the live webinar\, please register by clicking the link below. A recording of the webinar will be available for viewing shortly after the event. The recording will be available on the CARB-X website in the Apply > What CARB-X funds section. \nPlease click here to register.
URL:https://carb-x.org/event/carb-x-2019-funding-rounds-webinar/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="CARB-X":MAILTO:carbx@bu.edu
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20190221T170000
DTEND;TZID=Europe/Paris:20190221T183000
DTSTAMP:20260503T052858
CREATED:20190206T170743Z
LAST-MODIFIED:20190214T192431Z
UID:2345-1550768400-1550773800@carb-x.org
SUMMARY:Webinar - NIAID Resources to Facilitate Discovery & Development of Anti-Infectives
DESCRIPTION:Speakers include Ann Eakin\, Senior Scientific Officer Office of Biodefense\, Research Resources & Translational Research\, DMID/NIAID/NIH\, member of the CARB-X Joint Oversight Committee. \nIn this presentation\, Ann Eakin (US National Institute of Allergy and Infectious Diseases\, NIAID) will provide an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs\, vaccines and diagnostics targeting infectious diseases. The types of support that will be discussed are grants and contracts\, as well as preclinical and clinical research services that aim to reduce risk and advance product development efforts. Researchers from any country and from any type of institution (academia\, industry\, non-profit) are eligible to apply for nearly all types of support mechanisms offered by NIAID\, irrespective of prior or current NIH funding. \nAnn’s presentation will be complemented by a short presentation of Dan Pevear\, Founder and Senior Vice President\, Biology and Grants Development\, VenatoRx Pharmaceuticals\, in which he will share VenatoRx’ experience with NIAID support mechanisms. \nThe presentations will be followed by a Q&A session. \n 
URL:https://carb-x.org/event/webinar-niaid-resources-to-facilitate-discovery-development-of-anti-infectives/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
END:VCALENDAR